Clinical Trial Update: Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia [Phase 3]

View source ↗

Summary

A Phase 3 trial studied rivastigmine for Parkinsonian apathy in patients without dementia and has completed. The snippet does not include trial outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Sponsor: University Hospital, Lille | Conditions: Parkinson's Disease, Apathy | Phase 3 | Status: COMPLETED